Bortezomib and lenalidomide as front-line therapy for multiple myeloma

Leukemia and Lymphoma

Volumn 55, Issue 9, 2014, Pages 2024-2031

  Zou, Yandun ^a   Lin, Mingzhen ^b   Sheng, Zhixin ^b   Niu, Shaona ^c  

^a Guangdong Women and Children's Hospital   (China)

^b WEIFANG PEOPLE'S HOSPITAL   (China)

^c LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

Bortezomib; Lenalidomide; Multiple myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ARTICLE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; META ANALYSIS; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SECOND CANCER; THROMBOEMBOLISM; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; ODDS RATIO; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84906070876     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.847935     Document Type: Article

References (26)

1. Myeloma Trialist Collaborative Group (MTCG). Combination chemotherapy versus melphalan and prednisone as treatment of multiple myeloma: an overview of 6, 633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapYin multiple myeloma. N Engl J Med 1996; 335: 91-97.
3. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
4. Ries LAG, Harkins D, Krapcho M, editors. SEER cancer statistics review, 1975-2003[based on November 2005 SEER data submission, posted to the SEER web site, 2006]. Bethesda, MD: National Cancer Institute; 2006. Available from: http://seer.cancer.gov/csr/1975-2003/
5. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
6. Sonneveld P, Schmidt-Wolf I G, v an der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946-2955.
7. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapYin the phase III VISTA trial. J Clin Oncol 2010; 28: 2259-2266.
8. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus. dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075-2085.
9. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621-4629.
10. Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapYin multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120: 1589-1596.
11. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-1791.
12. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366: 1759-1769.
13. Erratum in: N Engl J Med 2012;367:285.
14. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and highdose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010; 116: 5838-5841.
15. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
16. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
17. P armar M K, T orri V, S tewart L. E xtracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
18. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
19. Berlin JA, Laird NM, Sacks HS, et al. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989; 8: 141-151.
20. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119: 4375-4382.
21. Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013; 31: 3279-3287.
22. Zeng Z, Lin J, Chen J. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Ann Hematol 2013; 92: 935-943.
23. W ang A, D uan Q, L iu X, et al. ( Bortezomib plus lenalidomide/ thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)- containing regimens as induction therapYin newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol 2012; 91: 1779-1184.
24. Kumar A, Hozo I, Wheatley K, et al. Th alidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol 2011; 86: 18-24.
25. Ye X, Huang J, Pan Q, et al. Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials. PLoS One 2013; 8: e72635.
26. D imopoulos M A, R ichardson P G, B randenburg N, et al. A review of second primary malignancYin patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119: 2764-2767